Year-over-year earnings per share growth for the last twelve months: Compugen Ltd. (CGEN)

Compugen (CGEN) - corporate logo

Immunotherapy development is independent of macroeconomics, and strictly controlled raw material logistics guarantee the stability of research. A comparison of quarterly EPS visualizes the outcome of these processes, where the parameter value equals 5.70. This approach confirms the effectiveness of the Compugen Ltd. (CGEN) strategy, which utilizes AI for cancer target discovery and the licensing of breakthroughs through robust patent protection.

Compugen Ltd (CGEN) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for Compugen Ltd. (CGEN)

- share price and expert price forecast:
Stock Price cgen.com|CGEN - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Compugen Limited|CGEN - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Compugen|CGEN - Company Net Assets|Market Cap to Net Assets Ratio cgen.com|CGEN - Company Total Assets
- debt and liquidity details:
Debt to Equity Compugen Ltd.|CGEN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity cgen.com|CGEN - Company Cumulative Debt|Debt to Book Value Compugen Limited|CGEN - Long-Term Indebtedness|Company Current Liabilities Compugen|Quick Ratio cgen.com
- earnings and market multiples details:
CGEN - Final Profit|Projected Future Earnings Compugen Ltd.|CGEN - Market Cap to Earnings|Future Price to Earnings cgen.com|CGEN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Compugen Limited|CGEN - Operating profit EBITDA|Earnings per share for the last twelve months Compugen|CGEN - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months cgen.com|CGEN - Earnings per share growth rate in current year|Earnings growth forecast for next year Compugen Ltd.
Comprehensive company analysis:Compugen Ltd, CGEN
Manufactured product of cgen.com

The market views Compugen Ltd. (CGEN) as a promising player in the high-tech immuno-oncology sector. This metric measures the percentage change in net earnings per share between the current and previous quarters, reflecting the efficiency of monetizing developments. By analyzing the quarterly EPS growth on the GURU.Markets platform, an investor can see a correlation between profits and success in creating unique antibodies. This trend captures financial stability while searching for new therapeutic targets. This asset belongs to the class of volatile biotechnology securities.

Competitors of Compugen Ltd.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Replimune Group, Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lyell.com (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months IOBT (IO Biotech Corp)|Year-over-year earnings per share growth rate for the last twelve months STRO|Quarterly EPS earnings growth INKT (MiNK Therapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|Intensity Tx - Quarterly EPS earnings growth|Sensei Biotherapeutics (SNSE) - Year-over-year net earnings per share growth for the last 12 months|Theriva Biologics (TOVX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Gritstone bio (GRTS)|Year-over-year earnings per share growth for the last twelve months Kineta Bio|Year-over-year net earnings per share growth for the last 12 months NexImmune Corporation (NEXI)|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics (TSBX)|VCNX: Year-over-year net earnings per share trend for the last twelve months|Harpoon Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months